Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study-Reference-Cited by-同舟云学术

Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

Published:2024-06-21 Issue: Volume: Page:1-7
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Dülgar Özgecan¹^ORCID,Türker Sema²,Başaran Gül³,Araz Murat⁴,Sümbül Ahmet Taner⁵,Çağlayan Dilek⁴,Gümüşay Özge³,Biter Sedat⁶,Konca Ahmet⁷,Özen Miraç⁸,Demir Hacer⁹,Özdemir Melek¹⁰,Karataş Fatih¹¹,Şahin Elif¹²,Çavdar Eyyüp¹³,Yasin Ayşe İrem¹⁴,Yaşar Alper¹⁵,Derin Sümeyra¹⁶,Pehlivan Metin¹⁷,Üyetürk Ümmügül¹⁸,Özdemir Özlem¹⁹,Kayıkçıoğlu Erkan²⁰,Ak Naziye²¹,Şakalar Teoman²²,Sakin Abdullah²³,Büyükşimşek Mahmut²⁴,Ay Seval²⁵,Ertürk İsmail²⁶,Akbaş Sinem²⁷,Bir Yücel Kadriye²⁸,Gümüş Mahmut²⁹

Affiliation:

1. Department of Medical Oncology, Health Science University, Umraniye Training and Research Hospital, Istanbul, Turkey

2. Department of Internal Medicine, Bahcesehir University, Istanbul, Turkey

3. Department of Medical Oncology, Acıbadem University, Istanbul, Turkey

4. Department of Medical Oncology, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey

5. Department of Medical Oncology, Medical Park Hospital Groups, Adana, Turkey

6. Department of Medical Oncology, Cukurova University, Faculty of Medicine, Adana, Turkey

7. Department of Medical Oncology, Gaziantep Univesity, Sahinbey Training and Research Hospital, Gaziantep, Turkey

8. Department of Medical Oncology, Sakarya University, Sakarya, Turkey

9. Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey

10. Department of Medical Oncology, Pamukkale University, Denizli, Turkey

11. Department of Medical Oncology, Karabuk University, Karabuk, Turkey

12. Department of Medical Oncology, Kocaeli University, İzmit, Turkey

13. Department of Medical Oncology, Tekirdag Namık Kemal University, Tekirdag, Turkey

14. Department of Medical Oncology, Bezmi Alem Vakıf University, Istanbul, Turkey

15. Department of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey

16. Department of Medical Oncology, Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey

17. Department of Medical Oncology, Zonguldak Ataturk State Hospital, Zonguldak, Turkey

18. Department of Medical Oncology, Okan University, Istanbul, Turkey

19. Department of Medical Oncology, Bozyaka Research and Training Hospital, İzmir, Turkey

20. Department of Medical Oncology, Süleyman Demirel University, Isparta, Turkey

21. Department of Medical Oncology, Yozgat City Hospital, Yozgat, Turkey

22. Department of Medical Oncology, Necip Fazıl City Hospital, Kahramanmaraş, Turkey

23. Department of Medical Oncology, Medipol University, Istanbul, Turkey

24. Department of Medical Oncology, University of Health Sciences-Adana City Training and Research Hospital, Adana, Turkey

25. Department of Medical Oncology, Balıkesir Atatürk City Hospital, Balıkesir, Turkey

26. Department of Medical Oncology, Ankara Gulhane Training and Research Hospital, Ankara, Turkey

27. Department of Medical Oncology, Koc University, Faculty of Medicine, Istanbul, Turkey

28. Department of Medical Oncology, Gazi University School of Medicine, Ankara, Turkey

29. Department of Medical Oncology, Medeniyet University, Faculty of Medicine, Istanbul, Turkey

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2024.2366683

Reference17 articles.

1. Trastuzumab emtansine: mechanisms of action and drug resistance

2. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

3. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

4. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study